Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

ATAI Life Sciences N.V. - Common Shares (NQ:ATAI)

2.410 -0.070 (-2.82%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 6, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about ATAI Life Sciences N.V. - Common Shares

< Previous 1 2
...
7 8 9 10 11 12 13 14 15
...
27 28 Next >
This Analyst Still Has Confidence In Atai Life Sciences' Pipeline Despite Recent Setbacks
Via Benzinga
Mind Medicine, Seelos Therapeutics Among Top Psychedelic Movers Of Today
Via Benzinga
Psyched: Psychedelics In Davos, Prince Harry In The 90s, Cathie Wood's Latest Moves And More
Psychedelics Take Center Stage In Davos Psychedelics will lead the conversation inside the Davos House of Health for a second year in a row this January. 
Via Benzinga
Psychedelic Stock Gainers And Losers From January 17, 2023
Via Benzinga
GH Research, Cybin Among Top Psychedelic Movers Of Today
Via Benzinga
Psychedelic Stock Gainers And Losers From January 13, 2023
Via Benzinga
Psychedelic Stock Gainers And Losers From January 11, 2023
Via Benzinga
Psychedelic Stock Gainers And Losers From January 10, 2023
Via Benzinga
What 4 Analyst Ratings Have To Say About ATAI Life Sciences
Via Benzinga
Intelgenx Technologies, Cybin Among Top Psychedelic Movers Of Today
Via Benzinga
Cathie Wood Reacts To Atai's Drastic Stock Plunge After Doomed Clinical Study Results
After atai Life Sciences (NASDAQ: ATAI) shared the results of subsidiary Perception Neuroscience’s Phase 2 trial of R-ketamine compound for TRD, the psyche 
Via Benzinga
Psychedelic Stock Gainers And Losers From January 9, 2023
Via Benzinga
atai Life Sciences Company GABA Therapeutics Announces Positive Final Results from Phase 1 Single and Multiple Ascending Dose Trial of GRX-917
From atai Life Sciences
Via GlobeNewswire
ATAI Life Sciences, Cybin Among Top Psychedelic Movers Of Today
Via Benzinga
Atai Life Sciences' Depression Candidate Faces Trial Setback, Shares Nosedive
Via Benzinga
Psychedelic Stock Gainers And Losers From January 5, 2023
Via Benzinga
My "Rags-To-Riches" Portfolio For 2023: An Introduction
The performance of cannabis, psychedelic and plant-based food stocks in 2022 were just horrible; is there any way to go but up? 
Via Talk Markets
atai Life Sciences' Drug Trial For Depression Fails To Deliver Expected Results, Stock Plunges
Clinical-stage psychedelics biotech atai Life Sciences (NASDAQ: ATAI) shared the results of its NYC-based subsidiary NYC-based Perception Neuroscience’s Phase 2a study of proprietary R-ketamine PCN-101... 
Via Benzinga
Dow Jumps 700 Points; S&P 500 Rises Over 2%
U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining around 700 points on Friday. 
Via Benzinga
Nasdaq Gains 1.5%; Fate Therapeutics Shares Plunge
U.S. stocks traded higher midway through trading, with the Dow Jones gaining more than 550 points on Friday. 
Via Benzinga
Seelos Therapeutics, Cybin Among Top Psychedelic Movers Of Today
Via Benzinga
Psychedelic Stock Gainers And Losers From January 2, 2023
Via Benzinga
Why Spruce Biosciences Shares Are Trading Higher By 100%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Gainers Swvl Holdings Corp. (NASDAQ: SWVL) surged 133% to $0.3218. Swvl recently announced the commencement of a strategic review process. 
Via Benzinga
Greenbrier, Fate Therapeutics, AnaptysBio And Some Other Big Stocks Moving Lower On Friday
U.S. stocks traded higher, with the Dow Jones gaining more than 500 points on Friday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
  During Friday's trading, 71 companies set new 52-week lows. 
Via Benzinga
Dow Rises Over 300 Points; US Adds 223,000 Jobs In December
U.S. stocks traded higher this morning, with the Dow Jones gaining more than 300 points on Friday. 
Via Benzinga
atai Life Sciences Announces Results from Phase 2a Trial of PCN-101 (R-ketamine) for Treatment-Resistant Depression
From atai Life Sciences
Via GlobeNewswire
Psychedelic Stock Gainers And Losers From January 3, 2023
Via Benzinga
What Happened With Psychedelics In The Last Year? 11 Key News Items, The Sector's Performance & Takeaways
What a year for psychedelics! 
Via Benzinga
6 Largest Psychedelic Drug Stocks Were -20% In December
The Psychedelic Drug Stocks Index, which tracks the six largest psychedelic stocks researching the treatment of mental illnesses based on the use of one or more psychedelic substances, continued to... 
Via Talk Markets
< Previous 1 2
...
7 8 9 10 11 12 13 14 15
...
27 28 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.